###begin article-title 0
###xml 37 45 37 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 37 44 <span type="species:ncbi:562">E. coli</span>
Structural analysis of inhibition of E. coli methionine aminopeptidase: implication of loop adaptability in selective inhibition of bacterial enzymes
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Methionine aminopeptidase is a potential target of future antibacterial and anticancer drugs. Structural analysis of complexes of the enzyme with its inhibitors provides valuable information for structure-based drug design efforts.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 406 411 <span type="species:ncbi:9606">human</span>
###xml 461 466 <span type="species:ncbi:9606">human</span>
###xml 578 583 <span type="species:ncbi:9606">human</span>
Five new X-ray structures of such enzyme-inhibitor complexes were obtained. Analysis of these and other three similar structures reveals the adaptability of a surface-exposed loop bearing Y62, H63, G64 and Y65 (the YHGY loop) that is an integral part of the substrate and inhibitor binding pocket. This adaptability is important for accommodating inhibitors with variations in size. When compared with the human isozymes, this loop either becomes buried in the human type I enzyme due to an N-terminal extension that covers its position or is replaced by a unique insert in the human type II enzyme.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 37 45 37 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 37 44 <span type="species:ncbi:562">E. coli</span>
###xml 273 278 <span type="species:ncbi:9606">human</span>
###xml 480 485 <span type="species:ncbi:9606">human</span>
The adaptability of the YHGY loop in E. coli methionine aminopeptidase, and likely in other bacterial methionine aminopeptidases, enables the enzyme active pocket to accommodate inhibitors of differing size. The differences in this adaptable loop between the bacterial and human methionine aminopeptidases is a structural feature that can be exploited to design inhibitors of bacterial methionine aminopeptidases as therapeutic agents with minimal inhibition of the corresponding human enzymes.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 243 260 243 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 268 291 268 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella typhimurium </italic>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 391 392 391 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 494 519 494 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae </italic>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 545 546 545 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 693 694 693 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 695 696 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 767 769 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 243 259 <span type="species:ncbi:562">Escherichia coli</span>
###xml 268 290 <span type="species:ncbi:90371">Salmonella typhimurium</span>
###xml 494 518 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
###xml 672 677 <span type="species:ncbi:9606">human</span>
###xml 754 759 <span type="species:ncbi:9606">human</span>
###xml 783 788 <span type="species:ncbi:9606">human</span>
Methionine aminopeptidase (MetAP) removes the N-terminal methionine residue from nascent proteins in all types of cells [1]. Prokaryotic cells express only one MetAP, and its essentiality was demonstrated by the lethality of its deletion from Escherichia coli [2] and Salmonella typhimurium [3]. MetAP is therefore a potential target for developing novel broad spectrum antibacterial drugs [4]. Eukaryotic cells have two types of MetAP (type I and type II), and deletion of both MetAP genes in Saccharomyces cerevisiae was shown to be lethal [5,6]. Fumagillin and its analogues TNP-470 and ovalicin are potent antiangiogenic compounds and are also selective inhibitors of human type II MetAP [7-9]. The antiproliferative bengamides inhibit both types of human MetAP [10]. Therefore, human MetAPs may also serve as targets for development of new anticancer therapeutics.
###end p 9
###begin p 10
###xml 187 188 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 188 190 188 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 198 200 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 237 239 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 480 482 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 483 485 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 656 664 655 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 720 721 719 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 722 724 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 725 727 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 856 858 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 859 861 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 919 921 918 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 922 924 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 925 927 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 958 960 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 961 963 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 984 986 983 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 987 989 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1358 1366 1357 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 1384 1386 1383 1385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1387 1389 1386 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1390 1392 1389 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1549 1551 1548 1550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1552 1554 1551 1553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1555 1557 1554 1556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 656 663 <span type="species:ncbi:562">E. coli</span>
###xml 698 703 <span type="species:ncbi:9606">human</span>
###xml 1358 1365 <span type="species:ncbi:562">E. coli</span>
Early MetAP inhibitors were derived from peptide substrates or the cleavage product methionine, such as the peptic inhibitor (3R)-amino-(2S)-hydroxyheptanoyl-L-Ala-L-Leu-L-Val-L-Phe-OMe (Ki 5 muM) [11] and norleucine phosphonate (NleP) [12]. Both are considered as transition state inhibitors. Although these compounds are not desired as therapeutic agents, structural studies of their complexes with MetAP have provided valuable insight of the catalysis and inhibition of MetAP [12-14]. Fumagillin, a natural product, and its analogues are a unique class of MetAP inhibitors that covalently modify a conserved histidine residue at the active site (H79 of E. coli MetAP, and the equivalent H231 of human type II MetAP) [9,15,16]. Several classes of non-peptidic and reversible MetAP inhibitors have been identified recently, such as furancarboxylic acids [17,18], thiabendazole and other thiazole-containing compounds [17,19-21], triazole-based derivatives [22-24], and sulfonamides [25,26]. However, structural analysis of these nonpeptidic inhibitors in complex with MetAP showed that inhibition by many of the thiazole and triazole-containing compounds and sulfonamides is metal-mediated, and they bind to the active site of enzyme through a divalent metal ion with one of the conserved active site histidines (most with H97, and some with H181; both are E. coli MetAP numbering) [19,21,25]. It has been pointed out that formation of such complexes may be an artefact during crystallization or in in vitro assays using high metal concentrations [14,19,27], and whether there are enough free metal ions available inside cells to form such inhibitor-enzyme complexes is a question.
###end p 10
###begin p 11
###xml 116 117 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 314 322 314 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 861 863 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 314 321 <span type="species:ncbi:562">E. coli</span>
MetAP was initially characterized as a Co(II) enzyme because of reproducible activation of the apoenzyme by Co(II) [5,28]. Many X-ray structures of MetAPs with or without a ligand bound [29] show a dinuclear metal site inside the active site pocket that has five conserved residues D97, D108, H171, E204 and E235 (E. coli MetAP numbering) as metal ligands and filled with two Co(II) ions. The metal ion used to form the inhibitor-enzyme complexes mentioned above is neither of the metal ions, but an additional one close to the dinuclear site. In addition to Co(II), other divalent metals such as Mn(II), Ni(II), Zn(II), and Fe(II) have been shown to activate the enzyme in vitro as well [30,31]. It is not known which of the metal ions is actually used by MetAP under physiological conditions, but speculation favors Fe(II), Zn(II) or Mn(II) for this role [23,31,32].
###end p 11
###begin p 12
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 787 795 787 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 928 936 928 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 991 992 991 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 787 794 <span type="species:ncbi:562">E. coli</span>
###xml 928 935 <span type="species:ncbi:562">E. coli</span>
By high throughput screening of a diverse chemical library of small organic compounds, we have discovered furancarboxylic acids as MetAP inhibitors with high selectivity for the Mn(II)-form of the enzyme [17]. Importantly, they remain potent as MetAP inhibitors at low and physiologically more relevant metal concentration [27]. X-ray structures showed that they directly interact with the two metals at the dinuclear site without requiring the additional metal for binding [17,33]. Several derivatives of the screening hits were synthesized to study structure-function relationships for their inhibitory potency and metalloform-selectivity [18]. To elucidate the chemical basis for metalloform-selective MetAP inhibition in greater detail, we have now carried out structural studies of E. coli MetAP in complex with these metalloform-selective inhibitors. We report here five new X-ray crystal structures of the Mn(II)-form of E. coli MetAP, each complexed with a different inhibitor (Fig. 1). Analysis of these and other complexes identifies an adaptable loop of the active site pocket as an important structural feature of the enzyme that may be exploited to achieve selective inhibition of bacterial MetAP enzymes vs. mammalian counterparts.
###end p 12
###begin p 13
###xml 0 56 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Chemical structures of the inhibitors used in this study</bold>
###xml 78 86 78 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 238 246 238 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 78 85 <span type="species:ncbi:562">E. coli</span>
###xml 238 245 <span type="species:ncbi:562">E. coli</span>
Chemical structures of the inhibitors used in this study. X-ray structures of E. coli MetAP complexed with 1-3 have been reported previously [17, 33], and those with 4-8 are reported here. They are potent inhibitors of the Mn(II)-form of E. coli MetAP with IC50 values of 0.51, 0.69, 0.29, 1.1, 0.56, 0.37, 1.6 and 1.2 muM, respectively [18].
###end p 13
###begin title 14
Results and Discussion
###end title 14
###begin title 15
###xml 21 29 21 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 21 28 <span type="species:ncbi:562">E. coli</span>
Overall structure of E. coli MetAP in complex with the inhibitors
###end title 15
###begin p 16
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
The crystals generated by hanging-drop method consistently produced high-quality diffraction data for structural solution to resolution from 1.6 to 1.9 A (Table 1). All eight structures, including the five new ones, have the typical "pita-bread" fold (Fig. 2A) found in other MetAP structures [29], and each of them contains two Mn(II) ions at the dinuclear metal site. A single molecule of inhibitor sits in the shallow active site pocket (Fig. 2B). A surface-exposed loop containing Y62, H63, G64 and Y65 (the YHGY loop) is an integral part of the active site pocket. Notably, this loop adapts different positions in these structures to accommodate different inhibitors, and the implications of this adaptability for inhibitor design will be discussed further below.
###end p 16
###begin p 17
###xml 21 29 21 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 0 62 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Overall structure of <italic>E. coli </italic>MetAP complexed with an inhibitor</bold>
###xml 151 153 151 153 <bold xmlns:xlink="http://www.w3.org/1999/xlink">4 </bold>
###xml 21 28 <span type="species:ncbi:562">E. coli</span>
Overall structure of E. coli MetAP complexed with an inhibitor. Ribbon (A) and surface (B) drawings are shown for one of the structures with inhibitor 4 situated at the active site. The two Mn(II) ions are shown as green spheres, and the inhibitor is shown as sticks (yellow, carbon; red, oxygen; and blue, nitrogen). In ribbon drawing, the secondary structures are coded as red for alpha-helices, yellow for beta-sheets, and green for loops and other structures. The YHGY loop (Y62, H63, G64 and Y65) is indicated by a red arrow.
###end p 17
###begin p 18
X-ray data collection and refinement statistics
###end p 18
###begin p 19
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
a Numbers given in parentheses corresponding to the outer shell of data.
###end p 19
###begin title 20
###xml 29 37 29 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 29 36 <span type="species:ncbi:562">E. coli</span>
Binding of the inhibitors to E. coli MetAP
###end title 20
###begin p 21
###xml 56 57 56 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">4</bold>
###xml 58 60 58 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8 </bold>
###xml 69 77 69 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 361 369 361 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 390 391 390 391 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1</bold>
###xml 392 394 392 394 <bold xmlns:xlink="http://www.w3.org/1999/xlink">3 </bold>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 478 479 478 479 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1</bold>
###xml 480 482 480 482 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8 </bold>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 801 802 801 802 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1</bold>
###xml 803 805 803 805 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8 </bold>
###xml 845 847 839 841 <bold xmlns:xlink="http://www.w3.org/1999/xlink">6 </bold>
###xml 878 879 866 867 <bold xmlns:xlink="http://www.w3.org/1999/xlink">4</bold>
###xml 69 76 <span type="species:ncbi:562">E. coli</span>
###xml 361 368 <span type="species:ncbi:562">E. coli</span>
Common features of the Mn(II)-form selective inhibitors 4-8 bound to E. coli MetAP in the five new structures are that all use their carboxylate group to coordinate with the two Mn(II) ions at the dinuclear metal site and all take a non-coplanar or twisted conformation for the two aromatic rings (Fig. 3), consistent with our previously reported structures of E. coli MetAP complexed with 1-3 [17]. The twisted conformation found in all of the Mn(II)-form-selective inhibitors 1-8 is in agreement with the requirement of a hydrophobic ortho-substitution, such as chlorine, on the phenyl ring for inhibitory activity [17,18]. This twisting is usually explained in terms of repulsion between ortho hydrogens or substituents in a planar conformation. The twist angles observed in the MetAP complexes of 1-8 range from the smallest 23.3degrees for 6 to the largest 52.9degrees for 4, suggesting that in general, the phenylfuran-based inhibitors dock into the active site in a conformation that may correspond to a minimum-energy solution conformation. This in turn would enhance their binding by decreasing the fraction of binding energy that would be "wasted" to distort the molecule to a less-favorable conformation in the bound state.
###end p 21
###begin p 22
###xml 54 62 54 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Binding modes of the inhibitors at the active site of <italic>E. coli </italic>MetAP</bold>
###xml 258 260 258 260 <bold xmlns:xlink="http://www.w3.org/1999/xlink">4 </bold>
###xml 265 267 265 267 <bold xmlns:xlink="http://www.w3.org/1999/xlink">5 </bold>
###xml 272 274 272 274 <bold xmlns:xlink="http://www.w3.org/1999/xlink">6 </bold>
###xml 279 281 279 281 <bold xmlns:xlink="http://www.w3.org/1999/xlink">7 </bold>
###xml 290 292 290 292 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8 </bold>
###xml 527 528 527 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 528 531 528 531 <sub xmlns:xlink="http://www.w3.org/1999/xlink">obs</sub>
###xml 532 533 532 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 533 538 533 538 <sub xmlns:xlink="http://www.w3.org/1999/xlink">calc </sub>
###xml 54 61 <span type="species:ncbi:562">E. coli</span>
Binding modes of the inhibitors at the active site of E. coli MetAP. In the stereo views, only five conserved residues that coordinate with Mn(II) ions (D97, D108, H171, E204, E235) and two conserved histdines (H79, H178) are shown. The bound inhibitors are 4 (A), 5 (B), 6 (C), 7 (D), and 8 (E), respectively. The colour scheme is as follows: gray, carbon (protein residues); yellow, carbon (inhibitor); blue, nitrogen; red, oxygen; green, chlorine; and cyan, fluorine. Mn(II) ions are shown as green spheres. SigmaA-weighted Fobs-Fcalc standard omit maps (inhibitor and metal ions were not included in the model for the structure-factor calculation) are shown superimposed on the refined structures as blue meshes contoured at 3.5 standard deviations of the resulting electron density map.
###end p 22
###begin title 23
Adaptability of the YHGY loop in the inhibitor binding pocket
###end title 23
###begin p 24
###xml 50 51 50 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1</bold>
###xml 52 54 52 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8 </bold>
###xml 301 302 297 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 503 504 499 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 897 899 893 895 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1 </bold>
###xml 903 904 899 900 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8</bold>
###xml 1248 1249 1236 1237 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8</bold>
###xml 1659 1660 1647 1648 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1</bold>
###xml 1661 1663 1649 1651 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8 </bold>
###xml 1687 1689 1675 1677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
With the eight structures with similar inhibitors 1-8 available, we aligned these structures to identify similarities, as well as differences, among them. All structures aligned well with root mean square deviations (rmsd) ranging from 0.112 to 0.356 A for the Calpha carbons of residues 4-256 (Table 2). With this level of overall similarity, it is very noticeable that some residues are essentially immobile while others occupy distinctly different positions when different inhibitors are bound (Fig. 4). The residues forming the dinuclear metal site (H171, D108, E204, E235 and D97), as well as the nearby residues S110, T202, F177, H178 and H79, show little change in position upon binding of any of these inhibitors. In contrast, residues Y62, H63, G64, and Y65 in the YHGY loop, as well as residue W221, moved significantly. The largest changes occur between complexes containing inhibitors 1 and 8, where the respective Calpha carbons of residues Y62, H63, G64 and Y65 differ in positions by 1.00, 1.58, 1.62 and 1.36 A, respectively. The rmsd value for all Calpha carbons of residues 4-256 is also the largest at 0.356 A between the two structures. Clearly, the loop is pushed outwards to accommodate the extra volume occupied by inhibitor 8, and the surface exposure of the loop allows it to more readily accommodate the inhibitor. The same is true for other inhibitors, and the loop show a great adaptability. This flexibility allows the binding pocket to adapt to different shapes of the bound inhibitors. In principle, there could be an energetic penalty to pay (in terms of weaker binding) for moving this loop. However, the fact that inhibitors 1-8 are roughly equipotent [18] suggests that any energetic penalty for moving the loop may be compensated by other favorable interactions, such as compensating desolvation effects.
###end p 24
###begin p 25
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Adaptability of residues to the bound inhibitors at the active site</bold>
###xml 136 137 136 137 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1</bold>
###xml 138 139 138 139 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8</bold>
###xml 484 485 484 485 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1</bold>
###xml 495 496 495 496 <bold xmlns:xlink="http://www.w3.org/1999/xlink">2</bold>
###xml 505 506 505 506 <bold xmlns:xlink="http://www.w3.org/1999/xlink">3</bold>
###xml 514 515 514 515 <bold xmlns:xlink="http://www.w3.org/1999/xlink">4</bold>
###xml 524 525 524 525 <bold xmlns:xlink="http://www.w3.org/1999/xlink">5</bold>
###xml 536 537 536 537 <bold xmlns:xlink="http://www.w3.org/1999/xlink">6</bold>
###xml 545 546 545 546 <bold xmlns:xlink="http://www.w3.org/1999/xlink">7</bold>
###xml 558 559 558 559 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8</bold>
Adaptability of residues to the bound inhibitors at the active site. In this stereo view, all eight structures, each with an inhibitor (1-8) bound, were superimposed. The inhibitors are shown as thick sticks, and the nearby protein residues are shown as thin sticks. The two Mn(II) ions are shown as spheres and labelled as Mn1 and Mn2. The YHGY loop and residues Y62, H63, Y65 and W221, as well as Mn(II) ions, of each structure are coloured the same as the corresponding inhibitor: 1, yellow; 2, green; 3, cyan; 4, black; 5, magenta; 6, blue; 7, grey; and 8, red.
###end p 25
###begin p 26
###xml 78 79 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
rmsd values generated by pair-wise comparisons of the eight complex structuresa
###end p 26
###begin p 27
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 72 73 72 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1</bold>
###xml 77 78 77 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">2</bold>
###xml 82 83 82 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">3</bold>
###xml 87 88 87 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">4</bold>
###xml 92 93 92 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink">5</bold>
###xml 97 98 97 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink">6</bold>
###xml 102 103 102 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink">7</bold>
###xml 111 112 111 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8</bold>
a The pdb codes and the bound inhibitors in the eight structures are: , 1; , 2, , 3; , 4; , 5; , 6; , 7; and , 8. These structures were aligned in a pair-wise fashion using the Calpha carbons of residues 4-256; the resulting rmsd values (in A) are presented. Numbers given in parentheses are reductions of rmsd (in A) when the same calculations were carried out with exclusion of residues 61-64 (the YHGY loop).
###end p 27
###begin title 28
Statistical analysis of the loop adaptability
###end title 28
###begin p 29
###xml 427 428 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
The YHGY loop (Y62, H63, G64, and Y65) forms part of the substrate and inhibitor binding pocket and has direct contact with the bound inhibitors. Positional uncertainty of these atoms in the structures is reflected in their B-factors. The B-factor values of atoms in this loop refined to high values in some of the structures (, , , ), indicating that these atoms are not as well ordered in those structures as in others (Fig. 5). However, the same atoms in some of the structures (, ) have low B-factors. The atoms in the YHGY loop do not consistently show high value for B-factors in the presence of a bound inhibitor, in comparison with other parts of the molecule. One of the reasons for this observation is that the value of B-factor is affected by interactions of the atom with the bound inhibitor. Therefore, the absolute value of their B-factors is not a good indicator of their adaptability.
###end p 29
###begin p 30
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Distribution of B factors over the residues of the complex structures</bold>
Distribution of B factors over the residues of the complex structures. Only B-factors for Calpha carbons are shown.
###end p 30
###begin p 31
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 391 392 391 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 527 528 527 528 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1</bold>
###xml 549 550 549 550 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8</bold>
Although the eight structures show good overall alignment as indicated by their small rmsd values during pair-wise comparisons (Table 2), the YHGY loop assumes different positions when different inhibitors are present (Fig. 4). It is revealing that when the residues 61-64 (the YHGY loop) are excluded from the rmsd calculation, the values dropped significantly for some of the pairs (Table 2), indicating a major contribution of the YHGY loop to the rmsd values for these pairs. Notably, the rmsd value between  (complex with 1) and  (complex with 8) showed the biggest drop from 0.356 A to 0.304 A with a reduction of 0.051 A (14%) just by removing four out of 253 residues for the rmsd calculation.
###end p 31
###begin p 32
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 358 359 354 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 752 753 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
To further assess the differences among the eight complex structures, we performed pair-wise comparisons using Cruickshank's diffraction precision index [34] with the addition of linear B-factor scaling as implemented in the program ESCET [35,36]. The Calpha carbons of residues 4-256 were used in calculating error-scaled difference distance matrices (Fig. 6). When the lower limit was set at the 4sigma level (where sigma is the uncertainty in the measurement of the difference), the only region that was found to be flexible was residues 61-67. If the limit was raised to 5sigma, the flexible region narrowed to residues 62-66. The error-scaled difference distance matrices calculated by ESCET are consistent with the rmsd values presented in Table 2. This analysis confirms that the YHGY loop (residues 61-64) shows greater flexibility than other parts of the molecule in response to differing active site ligands.
###end p 32
###begin p 33
###xml 0 108 0 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Error-scaled difference distance matrices generated by pair-wise comparisons of the eight complex structures</bold>
###xml 110 111 110 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 297 298 297 298 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1</bold>
###xml 302 303 302 303 <bold xmlns:xlink="http://www.w3.org/1999/xlink">2</bold>
###xml 307 308 307 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink">3</bold>
###xml 312 313 312 313 <bold xmlns:xlink="http://www.w3.org/1999/xlink">4</bold>
###xml 317 318 317 318 <bold xmlns:xlink="http://www.w3.org/1999/xlink">5</bold>
###xml 322 323 322 323 <bold xmlns:xlink="http://www.w3.org/1999/xlink">6</bold>
###xml 327 328 327 328 <bold xmlns:xlink="http://www.w3.org/1999/xlink">7</bold>
###xml 336 337 336 337 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8</bold>
###xml 831 832 823 824 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
Error-scaled difference distance matrices generated by pair-wise comparisons of the eight complex structures. A. Error-scaled difference distance matrices from pair-wise comparisons of all eight structures using ESCET program. The pdb codes and the bound inhibitors in the eight structures are: , 1; , 2, , 3; , 4; , 5; , 6; , 7; and , 8. All changes in distances smaller than the threshold 1sigma are shown in grey; differences between this lower limit and an upper limit of 8sigma are shown using a colour gradient where red stands for expansion and blue for contraction, light colours represent small changes and dark colours large changes; all differences larger than the upper limit are shown as full blue and full red, respectively. The gradients used for colour coding are also shown separately at the bottom of the figure. B. Enlarged one of the matrices in A, showing the comparison between  and . For clarity, the matrices underwent 2 x 2 binning (maintaining the element with the highest absolute value in the respective binning area) before being displayed.
###end p 33
###begin title 34
###xml 34 39 <span type="species:ncbi:9606">human</span>
Comparison with the structures of human type I and type II MetAPs
###end title 34
###begin p 35
###xml 47 55 47 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 289 297 289 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 341 349 341 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7C</xref>
###xml 47 54 <span type="species:ncbi:562">E. coli</span>
###xml 74 79 <span type="species:ncbi:9606">human</span>
###xml 233 238 <span type="species:ncbi:9606">human</span>
###xml 289 296 <span type="species:ncbi:562">E. coli</span>
###xml 325 330 <span type="species:ncbi:9606">human</span>
###xml 341 348 <span type="species:ncbi:562">E. coli</span>
###xml 502 507 <span type="species:ncbi:9606">human</span>
###xml 554 559 <span type="species:ncbi:9606">human</span>
We observed previously that some inhibitors of E. coli MetAP inhibit only human type I MetAP that is truncated at the N-terminus but not the full-length enzyme with an intact N-terminus [37]. As structures of both type I and type II human MetAPs are available, we aligned the structure of E. coli MetAP with those of the two human subtypes. E. coli MetAP is a typical bacterial MetAP, containing only a catalytic domain (Fig. 7C). On the other hand, mammalian MetAPs, including both type I and type II human MetAPs, have an N-terminal extension. Type II human MetAP has an extra insert, dissecting the catalytic domain into two fragments.
###end p 35
###begin p 36
###xml 30 38 30 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 0 60 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Structural comparison between <italic>E. coli </italic>MetAP and human MetAPs</bold>
###xml 75 83 75 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 136 138 136 138 <bold xmlns:xlink="http://www.w3.org/1999/xlink">4 </bold>
###xml 491 499 491 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 30 37 <span type="species:ncbi:562">E. coli</span>
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 75 82 <span type="species:ncbi:562">E. coli</span>
###xml 174 179 <span type="species:ncbi:9606">human</span>
###xml 308 313 <span type="species:ncbi:9606">human</span>
###xml 491 498 <span type="species:ncbi:562">E. coli</span>
###xml 509 514 <span type="species:ncbi:9606">human</span>
Structural comparison between E. coli MetAP and human MetAPs. Structure of E. coli MetAP used in the overlays is the one complexed with 4 and coloured grey. (A) Overlay with human type I MetAP (PDB code ) that is coloured cyan for the catalytic domain and blue for the N-terminal extension. (B) Overlay with human type II MetAP (PDB code ) that is coloured magenta for the catalytic domain, orange for the N-terminal extension and red for the insert. (C) Schematic drawing of the domains in E. coli MetAP and human MetAPs.
###end p 36
###begin p 37
###xml 32 40 32 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 223 231 223 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 32 39 <span type="species:ncbi:562">E. coli</span>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 114 119 <span type="species:ncbi:9606">human</span>
###xml 223 230 <span type="species:ncbi:562">E. coli</span>
###xml 266 271 <span type="species:ncbi:9606">human</span>
###xml 549 554 <span type="species:ncbi:9606">human</span>
By overlaying the structures of E. coli MetAP and human type I MetAP, we see that the N-terminal extension of the human enzyme wraps around the enzyme surface and covers the YHGY loop (Fig. 7A). The surface-exposed loop in E. coli MetAP now becomes mostly buried in human type I enzyme. This could greatly reduce the plasticity of the loop and make the inhibitor binding pocket much less tolerant to structural variations in inhibitor molecules. This change is consistent with our previous observation on inhibition of the truncated and full length human type I MetAPs [37], and the partially buried nature of the loop could make it less adaptable for the inhibitors of differing size.
###end p 37
###begin p 38
###xml 34 42 34 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 571 579 571 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 34 41 <span type="species:ncbi:562">E. coli</span>
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 135 140 <span type="species:ncbi:9606">human</span>
###xml 571 578 <span type="species:ncbi:562">E. coli</span>
###xml 633 638 <span type="species:ncbi:9606">human</span>
###xml 713 718 <span type="species:ncbi:9606">human</span>
In addition, an overlaying of the E. coli MetAP and human type II MetAP structures reveals that the YHGY loop is not present at all in human type II MetAP, and instead, its position is now occupied by an insert, unique to type II MetAP (Fig. 4B). The insert of approximately 65 residues forms a distinct globular domain and is an integral part of the active site pocket. The adaptability of its binding pocket may be analyzed when more complex structures are available. However, differences in adaptability are likely found because the YHGY loop is part of the pocket in E. coli MetAP and it is substituted by the globular insert in human type II MetAP. It is interesting to note that the N-terminal extension of human type II enzyme is located away from the active site.
###end p 38
###begin title 39
Implications of the adaptability of the YHGY loop in developing MetAP inhibitors as antibiotics
###end title 39
###begin p 40
###xml 448 456 448 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 448 455 <span type="species:ncbi:562">E. coli</span>
###xml 525 530 <span type="species:ncbi:9606">human</span>
###xml 696 701 <span type="species:ncbi:9606">human</span>
###xml 856 861 <span type="species:ncbi:9606">human</span>
Structure-based drug design takes advantage of the structural information of a medicinally important protein, especially at the active site, to guide the design and development of protein ligands to achieve desired potency and selectivity. Bacterial MetAP enzymes are the simplest in the MetAP family and contain only a catalytic domain. Most bacterial MetAPs, with exception of achaeal enzymes, belong to the type I MetAP family and are homologs. E. coli MetAP, as a typical bacterial MetAP, has high sequence homology with human type I MetAP within the catalytic domain (121 out of 264 residues are identical). It is certainly desirable to identify the differences between bacterial MetAPs and human counterparts so that MetAP inhibitors as potential antibiotics will selectively inhibit only bacterial MetAPs. The N-terminal extension and the insert in human MetAPs are the extra structural elements that can be potentially exploited to design selective inhibitors for bacterial MetAPs.
###end p 40
###begin p 41
###xml 28 36 28 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 685 693 685 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 28 35 <span type="species:ncbi:562">E. coli</span>
###xml 515 520 <span type="species:ncbi:9606">human</span>
###xml 581 586 <span type="species:ncbi:9606">human</span>
###xml 685 692 <span type="species:ncbi:562">E. coli</span>
###xml 755 760 <span type="species:ncbi:9606">human</span>
As more X-ray structures of E. coli MetAP in complex with inhibitors have become available, we now can compare the structures and characterize the binding of different inhibitors. Careful structural analysis of these structures reveals the adaptability of the YHGY loop (Y62, H63, G64 and Y65) that accommodates inhibitors of differing size. The adaptability of this loop in bacterial enzymes could be an important structural feature to exploit because the loop is partially occluded by the N-terminal extension in human type I MetAP [38-42] and is replaced by an unique insert in human type II MetAP [15]. Consequently, the ability to adapt multiple conformations within this loop of E. coli MetAP, and likely of other bacterial MetAPs, may not exist in human MetAPs and could be utilized to steer MetAP inhibitors towards selective inhibition of the bacterial enzymes.
###end p 41
###begin p 42
This observation emphasizes the importance in considering the dynamics of ligand binding to enzymes in modeling inhibitors into a binding site on a protein, especially during the virtual screening of MetAP inhibitors. A rigid active site would appear to be relatively intolerant of anything but a nearly perfect fit or a slightly undersized ligand, but a flexible site would be more forgiving and tolerant of a wider range of structures. Molecules that might appear to fit poorly based on a rigid structure model may in reality fit quite well because of loop movement. Recognizing and utilizing this flexibility could be beneficial, for example, for optimizing the potency and selectivity of an inhibitor or fine-tuning its biopharmaceutical properties.
###end p 42
###begin title 43
Conclusion
###end title 43
###begin p 44
###xml 40 48 40 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 40 47 <span type="species:ncbi:562">E. coli</span>
###xml 466 471 <span type="species:ncbi:9606">human</span>
###xml 529 534 <span type="species:ncbi:9606">human</span>
###xml 697 702 <span type="species:ncbi:9606">human</span>
Structural analysis of the complexes of E. coli MetAP with a series of related inhibitors reveals the ability of the surface-exposed loop containing the sequence YHGY to adapt multiple conformations to better complement the structural features of bound ligands. This adaptable loop likely exists in all bacterial MetAPs based on sequence similarity and the surface-exposed nature of the loop. However, this loop is partially buried by an N-terminal extension in the human type I MetAP and substituted by a globular insert in the human type II MetAP. The difference in ability of the substrate/inhibitor binding pocket to adapt to a wide range of ligand sizes may distinguish bacterial MetAPs from human MetAPs and could be exploited to design selective inhibitors of bacterial MetAPs.
###end p 44
###begin title 45
Methods
###end title 45
###begin title 46
Preparation of the protein and compounds
###end title 46
###begin p 47
###xml 16 24 16 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 75 76 75 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1</bold>
###xml 77 78 77 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">3</bold>
###xml 80 82 80 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink">6 </bold>
###xml 86 88 86 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">7 </bold>
###xml 156 157 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 163 165 163 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 220 221 220 221 <bold xmlns:xlink="http://www.w3.org/1999/xlink">4</bold>
###xml 223 225 223 225 <bold xmlns:xlink="http://www.w3.org/1999/xlink">5 </bold>
###xml 229 231 229 231 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8 </bold>
###xml 348 356 348 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 16 23 <span type="species:ncbi:562">E. coli</span>
###xml 348 355 <span type="species:ncbi:562">E. coli</span>
The recombinant E. coli MetAP was purified as an apoenzyme [30]. Compounds 1-3, 6 and 7 were purchased from ChemBridge (San Diego, CA) and characterized by 1H and 13C NMR and high resolution mass spectrometry. Compounds 4, 5 and 8 were synthesized in our laboratory. Their inhibitory activities on the Co(II)-, Mn(II)-, Ni(II)- and Fe(II)-forms of E. coli MetAP have been described previously [17,18].
###end p 47
###begin title 48
Crystallization Conditions
###end title 48
###begin p 49
###xml 579 580 571 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 641 643 633 635 <bold xmlns:xlink="http://www.w3.org/1999/xlink">4 </bold>
###xml 647 649 639 641 <bold xmlns:xlink="http://www.w3.org/1999/xlink">5 </bold>
###xml 662 663 654 655 <bold xmlns:xlink="http://www.w3.org/1999/xlink">6</bold>
###xml 664 665 656 657 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8</bold>
Initial crystallization conditions were determined using Crystal Screen and Index HT kits in 96-well sitting-drop plates (Hampton Research) at room temperature. Final crystals of the enzyme-inhibitor complexes were obtained independently by the hanging-drop vapour-diffusion method at 18-20degreesC. Inhibitors (200 mM in DMSO) were added to concentrated apoenzyme (12 mg/ml, 0.4 mM) in 10 mM MOPS pH 7.0. Hanging drops contained 3 mul protein solution mixed with 3 mul reservoir solution. The reservoir solution consisted of 10-15% PEG 20,000, 0.1 M MES (pH 6.5) and 0.2 mM MnCl2. The concentration ratio of inhibitor:apoenzyme was 5:1 for 4 and 5 and 10:1 for 6-8, and that of metal:apoenzyme was 5:1.
###end p 49
###begin title 50
Data collection and structural refinement
###end title 50
###begin p 51
###xml 262 264 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 309 311 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 335 337 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 399 401 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 533 541 521 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 681 683 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 738 740 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1154 1156 1142 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1346 1347 1334 1335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1347 1350 1335 1338 <sub xmlns:xlink="http://www.w3.org/1999/xlink">obs</sub>
###xml 1351 1352 1339 1340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1352 1357 1340 1345 <sub xmlns:xlink="http://www.w3.org/1999/xlink">calc </sub>
###xml 1459 1460 1447 1448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1460 1463 1448 1451 <sub xmlns:xlink="http://www.w3.org/1999/xlink">obs</sub>
###xml 1464 1465 1452 1453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1465 1470 1453 1458 <sub xmlns:xlink="http://www.w3.org/1999/xlink">calc </sub>
###xml 1474 1475 1462 1463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1475 1478 1463 1466 <sub xmlns:xlink="http://www.w3.org/1999/xlink">obs</sub>
###xml 1479 1480 1467 1468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1480 1485 1468 1473 <sub xmlns:xlink="http://www.w3.org/1999/xlink">calc </sub>
###xml 1539 1540 1527 1528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1540 1543 1528 1531 <sub xmlns:xlink="http://www.w3.org/1999/xlink">obs</sub>
###xml 1544 1545 1532 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1545 1550 1533 1538 <sub xmlns:xlink="http://www.w3.org/1999/xlink">calc </sub>
###xml 1747 1749 1735 1737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 2045 2046 2033 2034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 533 540 <span type="species:ncbi:562">E. coli</span>
Data were collected on an R-Axis IV imaging plate detector with a Rigaku rotating anode generator operated at 50 kV and 100 mA. Images were recorded over 180degrees in 0.5degrees increments at 100 K. Raw reflection data were indexed and integrated using MOSFLM [43] and merged and scaled using SCALA in CCP4 [44] with CCP4i interface [45]. Analysis of the estimated solvent content of each crystal [46] indicated only one molecule of the enzyme per asymmetric unit in all cases. The coordinates of our previously solved structure of E. coli MetAP (PDB code ) with ligand, metal ions and water molecules removed were used as the search model for molecular replacement using MOLREP [47]. Crystallographic refinement was performed with CNS [48]. The refinement was monitored using 10% of the reflections set aside for free R factor analysis throughout the whole refinement process. Initial refinement started with simulated annealing with a starting temperature at 4000 K and 25 K drop in temperature per cycle. The models were refined with iterative cycles of individual B factor refinement, positional refinement, and manual model building using WinCoot [49]. The Mn(II) atoms were not included in the initial refinement procedure to reduce the model bias in phases and were then added to the model to the center of the peak in the Mn(II)-omitted Fobs-Fcalc electron density map. The ligand and water molecules were added when the electron densities shown in 2Fobs-Fcalc and Fobs-Fcalc maps for their placement were unequivocal. The final 2Fobs-Fcalc maps showed clear electron density for most of the atoms except for a few side chains at the molecular surface. The final models for all of the structures were analyzed using the program PROCHECK [50], and all have 99.6% of residues were in the allowed region of their respective Ramachandran plots. The atomic coordinates and structure factors for the structures have been deposited in the Protein Data Bank. Statistic parameters in data collection and structural refinement are shown in Table 1.
###end p 51
###begin title 52
Structural analysis
###end title 52
###begin p 53
###xml 36 38 36 38 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
Structures were aligned with PYMOL [51] using the "align" command, and rmsd values were calculated with "rms" command after pair-wise alignment. The program ESCET [35,36] was used to make an objective analysis of the conformational variability of the eight structures , , , , , ,  and . All drawings for protein structures in the figures were generated using PYMOL.
###end p 53
###begin title 54
Authors' contributions
###end title 54
###begin p 55
###xml 33 34 33 34 <bold xmlns:xlink="http://www.w3.org/1999/xlink">4</bold>
###xml 36 38 36 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink">5 </bold>
###xml 42 44 42 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink">8 </bold>
QQH and FJN prepared the ligands 4, 5 and 8 used in this study. SXX carried out the crystallization experiments and data collection. ZQM performed the data processing and structural modeling. TDH carried out the computational ESCET analysis of the structures. QZY designed the study, carried out the structural analysis, and wrote the manuscript. All authors read and approved the final manuscript.
###end p 55
###begin title 56
Acknowledgements
###end title 56
###begin p 57
We thank Dr. Min Huang and Dr. Robert P. Hanzlik for helpful discussions, Dr. Wei-Jun Huang for his assistant in X-ray data collection, and Dr. Thomas Schneider for his program ESCET used in calculating error-scaled difference distance matrices. This research was supported by NIH Grants AI065898, RR015563 and RR016475 (to QZY). High Throughput Screening Laboratory and Protein Structure Laboratory were supported by NIH Grants RR015563 and RR017708 from COBRE program of National Center for Research Resources, University of Kansas, and Kansas Technology Enterprise Corporation.
###end p 57
###begin article-title 58
N-terminal processing: the methionine aminopeptidase and N alpha-acetyl transferase families
###end article-title 58
###begin article-title 59
###xml 34 50 <span type="species:ncbi:562">Escherichia coli</span>
Methionine aminopeptidase gene of Escherichia coli is essential for cell growth
###end article-title 59
###begin article-title 60
###xml 29 51 <span type="species:ncbi:90371">Salmonella typhimurium</span>
pepM is an essential gene in Salmonella typhimurium
###end article-title 60
###begin article-title 61
Methionine in and out of proteins: targets for drug design
###end article-title 61
###begin article-title 62
Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes
###end article-title 62
###begin article-title 63
###xml 37 61 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Amino-terminal protein processing in Saccharomyces cerevisiae is an essential function that requires two distinct methionine aminopeptidases
###end article-title 63
###begin article-title 64
Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2
###end article-title 64
###begin article-title 65
Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin
###end article-title 65
###begin article-title 66
The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2
###end article-title 66
###begin article-title 67
Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitors
###end article-title 67
###begin article-title 68
Synthesis of (3R)-amino-(2S)-hydroxy amino acids for inhibition of methionine aminopeptidase-1
###end article-title 68
###begin article-title 69
###xml 31 47 <span type="species:ncbi:562">Escherichia coli</span>
Insights into the mechanism of Escherichia coli methionine aminopeptidase from the structural analysis of reaction products and phosphorus-based transition-state analogues
###end article-title 69
###begin article-title 70
###xml 0 16 <span type="species:ncbi:562">Escherichia coli</span>
Escherichia coli methionine aminopeptidase: implications of crystallographic analyses of the native, mutant, and inhibited enzymes for the mechanism of catalysis
###end article-title 70
###begin article-title 71
Structural basis of catalysis by monometalated methionine aminopeptidase
###end article-title 71
###begin article-title 72
###xml 13 18 <span type="species:ncbi:9606">human</span>
Structure of human methionine aminopeptidase-2 complexed with fumagillin
###end article-title 72
###begin article-title 73
###xml 98 114 <span type="species:ncbi:562">Escherichia coli</span>
The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase
###end article-title 73
###begin article-title 74
###xml 36 52 <span type="species:ncbi:562">escherichia coli</span>
Metalloform-selective inhibitors of escherichia coli methionine aminopeptidase and X-ray structure of a Mn(II)-form enzyme complexed with an inhibitor
###end article-title 74
###begin article-title 75
###xml 115 131 <span type="species:ncbi:562">Escherichia coli</span>
Metalloform-selective inhibition: Synthesis and structure-activity analysis of Mn(II)-form-selective inhibitors of Escherichia coli methionine aminopeptidase
###end article-title 75
###begin article-title 76
Metal ions as cofactors for the binding of inhibitors to methionine aminopeptidase: A critical view of the relevance of in vitro metalloenzyme assays
###end article-title 76
###begin article-title 77
###xml 87 103 <span type="species:ncbi:562">Escherichia coli</span>
###xml 108 132 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Discovery and structural modification of inhibitors of methionine aminopeptidases from Escherichia coli and Saccharomyces cerevisiae
###end article-title 77
###begin article-title 78
Crystal structures of Staphylococcusaureus methionine aminopeptidase complexed with keto heterocycle and aminoketone inhibitors reveal the formation of a tetrahedral intermediate
###end article-title 78
###begin article-title 79
###xml 35 56 <span type="species:ncbi:1280">Staphylococcus aureus</span>
The 1.15A crystal structure of the Staphylococcus aureus methionyl-aminopeptidase and complexes with triazole based inhibitors
###end article-title 79
###begin article-title 80
Physiologically relevant metal cofactor for methionine aminopeptidase-2 is manganese
###end article-title 80
###begin article-title 81
###xml 153 156 <span type="species:ncbi:10116">rat</span>
Small molecule inhibitors of methionine aminopeptidase type 2 (MetAP-2) fail to inhibit endothelial cell proliferation or formation of microvessels from rat aortic rings in vitro
###end article-title 81
###begin article-title 82
Metal mediated inhibition of methionine aminopeptidase by quinolinyl sulfonamides
###end article-title 82
###begin article-title 83
Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties
###end article-title 83
###begin article-title 84
Inhibition of Monometalated Methionine Aminopeptidase: Inhibitor Discovery and Crystallographic Analysis
###end article-title 84
###begin article-title 85
###xml 65 81 <span type="species:ncbi:562">Escherichia coli</span>
Structure of the cobalt-dependent methionine aminopeptidase from Escherichia coli: a new type of proteolytic enzyme
###end article-title 85
###begin article-title 86
Structure and function of the methionine aminopeptidases
###end article-title 86
###begin article-title 87
Specificity for inhibitors of metal-substituted methionine aminopeptidase
###end article-title 87
###begin article-title 88
###xml 34 50 <span type="species:ncbi:562">Escherichia coli</span>
The methionyl aminopeptidase from Escherichia coli can function as an iron(II) enzyme
###end article-title 88
###begin article-title 89
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast methionine aminopeptidase I can utilize either Zn2+ or Co2+ as a cofactor: a case of mistaken identity?
###end article-title 89
###begin article-title 90
Structural analysis of metalloform-selective inhibition of methionine aminopeptidase
###end article-title 90
###begin article-title 91
Remarks about protein structure precision
###end article-title 91
###begin article-title 92
Objective comparison of protein structures: error-scaled difference distance matrices
###end article-title 92
###begin article-title 93
A genetic algorithm for the identification of conformationally invariant regions in protein molecules
###end article-title 93
###begin article-title 94
###xml 53 58 <span type="species:ncbi:9606">human</span>
###xml 101 117 <span type="species:ncbi:562">Escherichia coli</span>
Characterization of full length and truncated type I human methionine aminopeptidases expressed from Escherichia coli
###end article-title 94
###begin article-title 95
###xml 75 80 <span type="species:ncbi:9606">human</span>
Structural basis for the functional differences between type I and type II human methionine aminopeptidases
###end article-title 95
###begin article-title 96
###xml 81 86 <span type="species:ncbi:9606">human</span>
Structure of the angiogenesis inhibitor ovalicin bound to its noncognate target, human Type 1 methionine aminopeptidase
###end article-title 96
###begin article-title 97
###xml 89 115 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
Identification of an SH3-binding motif in a new class of methionine aminopeptidases from Mycobacterium tuberculosis suggests a mode of interaction with the ribosome
###end article-title 97
###begin article-title 98
###xml 56 61 <span type="species:ncbi:9606">human</span>
Identification of pyridinylpyrimidines as inhibitors of human methionine aminopeptidases
###end article-title 98
###begin article-title 99
###xml 38 43 <span type="species:ncbi:9606">human</span>
Elucidation of the function of type 1 human methionine aminopeptidase during cell cycle progression
###end article-title 99
###begin article-title 100
Recent changes to the MOSFLM package for processing film and image plate data
###end article-title 100
###begin article-title 101
The CCP4 Suite: Programs for Protein Crystallography
###end article-title 101
###begin article-title 102
A graphical user interface to the CCP4 program suite
###end article-title 102
###begin article-title 103
Matthews coefficient probabilities: Improved estimates for unit cell contents of proteins, DNA, and protein-nucleic acid complex crystals
###end article-title 103
###begin article-title 104
MOLREP: an Automated Program for Molecular Replacement
###end article-title 104
###begin article-title 105
Crystallography & NMR system: A new software suite for macromolecular structure determination
###end article-title 105
###begin article-title 106
Coot: model-building tools for molecular graphics
###end article-title 106
###begin article-title 107
PROCHECK: a program to check the stereochemical quality of protein structures
###end article-title 107
###begin article-title 108
The PyMOL Molecular Graphics System
###end article-title 108

